| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis
|
Arbyn, Marc
|
|
|
23 |
7 |
p. 950-960
|
artikel
|
| 2 |
Amended bipartisan bill to expand clinical trial options for paediatric cancer in the USA
|
Das, Manjulika
|
|
|
23 |
7 |
p. 841
|
artikel
|
| 3 |
2022 ASCO Annual Meeting
|
Collingridge, David
|
|
|
23 |
7 |
p. 844
|
artikel
|
| 4 |
Awareness campaigns and cancer screening
|
The Lancet Oncology,
|
|
|
23 |
7 |
p. 829
|
artikel
|
| 5 |
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)
|
Agarwal, Neeraj
|
|
|
23 |
7 |
p. 899-909
|
artikel
|
| 6 |
Centers for Disease Control and Prevention invest in cancer prevention programmes
|
Das, Manjulika
|
|
|
23 |
7 |
p. e320
|
artikel
|
| 7 |
Conflict in Tigray impeding basic care for patients with cancer
|
Makoni, Munyaradzi
|
|
|
23 |
7 |
p. 842
|
artikel
|
| 8 |
Correction to Lancet Oncol 2022; 23: 304–16
|
|
|
|
23 |
7 |
p. e319
|
artikel
|
| 9 |
Correction to Lancet Oncol 2022; 23: 104–14
|
|
|
|
23 |
7 |
p. e319
|
artikel
|
| 10 |
Correction to Lancet Oncol 2022; 23: 888–98
|
|
|
|
23 |
7 |
p. e319
|
artikel
|
| 11 |
Efficacy in randomised trials: the time matters
|
Ottaiano, Alessandro
|
|
|
23 |
7 |
p. 839-840
|
artikel
|
| 12 |
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
|
Howell, Sacha J
|
|
|
23 |
7 |
p. 851-864
|
artikel
|
| 13 |
How molecularly similar are primary and metastatic tissues in renal cell carcinoma?
|
Kahya, Burcu Ulaş
|
|
|
23 |
7 |
p. e316
|
artikel
|
| 14 |
How molecularly similar are primary and metastatic tissues in renal cell carcinoma? – Authors’ reply
|
Vano, Yann-Alexandre
|
|
|
23 |
7 |
p. e317
|
artikel
|
| 15 |
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
|
Oosting, Sjoukje F
|
|
|
23 |
7 |
p. 833-835
|
artikel
|
| 16 |
Immunotherapy in colorectal cancer: an unmet need deserving of change
|
Elez, Elena
|
|
|
23 |
7 |
p. 830-831
|
artikel
|
| 17 |
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
|
Farge, Dominique
|
|
|
23 |
7 |
p. e334-e347
|
artikel
|
| 18 |
MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study
|
Ehdaie, Behfar
|
|
|
23 |
7 |
p. 910-918
|
artikel
|
| 19 |
Multi-cancer early detection tests for cancer screening: a behavioural science perspective
|
Marlow, Laura A V
|
|
|
23 |
7 |
p. 837-839
|
artikel
|
| 20 |
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
|
Motzer, Robert J
|
|
|
23 |
7 |
p. 888-898
|
artikel
|
| 21 |
Objects and stories in cancer science
|
Lucas, Catherine
|
|
|
23 |
7 |
p. 849-850
|
artikel
|
| 22 |
Optimal molecular selection to benefit from nivolumab–ipilimumab in clear-cell renal cell carcinoma
|
Vano, Yann-Alexandre
|
|
|
23 |
7 |
p. e318
|
artikel
|
| 23 |
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study
|
Pinato, David J
|
|
|
23 |
7 |
p. 865-875
|
artikel
|
| 24 |
Patients with cancer in Louisiana denied fertility preservation cover
|
Gourd, Elizabeth
|
|
|
23 |
7 |
p. 843
|
artikel
|
| 25 |
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial
|
Shing, Jaimie Z
|
|
|
23 |
7 |
p. 940-949
|
artikel
|
| 26 |
Radiotherapy in conflict: lessons from Ukraine
|
Price, Patricia
|
|
|
23 |
7 |
p. 845-847
|
artikel
|
| 27 |
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations
|
Ganguly, Shuvadeep
|
|
|
23 |
7 |
p. e314
|
artikel
|
| 28 |
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations – Authors' reply
|
Kristeleit, Rebecca
|
|
|
23 |
7 |
p. e315
|
artikel
|
| 29 |
Sacral insufficiency fracture after treatment for cervical cancer
|
Mathew, John M
|
|
|
23 |
7 |
p. e359
|
artikel
|
| 30 |
Should chemoradiotherapy be standard to maximise cure in localised gastro-oesophageal cancer?
|
Reynolds, John V
|
|
|
23 |
7 |
p. 847-849
|
artikel
|
| 31 |
Stereotactic radiosurgery for patients with small-cell lung cancer brain metastases
|
Rieken, Stefan
|
|
|
23 |
7 |
p. 832-833
|
artikel
|
| 32 |
Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis
|
Gaebe, Karolina
|
|
|
23 |
7 |
p. 931-939
|
artikel
|
| 33 |
Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective
|
Teran, Enrique
|
|
|
23 |
7 |
p. e348-e358
|
artikel
|
| 34 |
Systemic considerations for the surgical treatment of spinal metastatic disease: a scoping literature review
|
MacLean, Mark A
|
|
|
23 |
7 |
p. e321-e333
|
artikel
|
| 35 |
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
|
Antoniotti, Carlotta
|
|
|
23 |
7 |
p. 876-887
|
artikel
|
| 36 |
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
|
Clamp, Andrew R
|
|
|
23 |
7 |
p. 919-930
|
artikel
|
| 37 |
When competition is not enough: leveraging US policies to curb oral anticancer drug costs
|
Potnis, Kunal C
|
|
|
23 |
7 |
p. 836-837
|
artikel
|
Tijdschrift beschrijving